|
| BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence. |
|---|
|
   |
| We put BICX in front of you last week, and saw a quick upside opportunity for 10-15% gains on a day that saw the stock up as much as 30%. Watch for big news in the morning! |
|
 Hot Stock to Watch |
Company: Biocorrx, Inc. (Pink Sheets: BICX)
|
End of Day:
Price: 0.0257
Change (%): + 0.0055 (27.23)
Volume: 13,430 |
 |
The BioCorRx® Recovery Program, a non-addictive medication-assisted treatment (MAT) program, consists of two main components.
The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, Naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids.
The second component of the program developed by BioCorRx, Inc. is a one on one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long term naltrexone treatment.
Recent News
Alpine Creek and BioCorRx Announce Major Investment Into BioCorRx
SANTA ANA, CA--(Marketwired - Jun 20, 2016) - Alpine Creek Capital Partners ("Alpine Creek") and BioCorRx, Inc. (OTC PINK: BICX) ("BioCorRx" or "the Company") are pleased to announce an investment by Alpine Creek in the Company. The Company specializes in solutions for alcohol and opioid addiction treatment using its proprietary, non-addictive medication-assisted treatment (MAT) program called the BioCorRx® Recovery Program. The Company has the worldwide rights (except in Australia and New Zealand) to a highly effective, proprietary implant formulation of an FDA-approved medicine, naltrexone. After being surgically implanted by a medical professional, the naltrexone implant can significantly reduce cravings for alcohol or opioids for several months, depending on individual metabolism rates. In addition to the implant formulation, and perhaps more important, is the Company's comprehensive counseling program that was developed by addiction experts specific to individuals undergoing treatment with any form of sustained-release naltrexone.
Travis Mullen, Managing Partner of Alpine Creek Capital Partners, said, "We couldn't be more excited about our investment in BioCorRx and the cutting edge program they have in place. The BioCorRx® Recovery Program which includes this naltrexone delivery system coupled with the tangible counseling program is literally saving lives and we look forward to arming as many families as possible with this amazing tool for their battle against alcohol or opioid addiction."
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. Small Cap Voice received 500 dollars from the company on 7-13-16 for a one day email campaign. |
About Penny Stocks |
|
|
